The Effect of Induced Antibodies with Respect to Neutralization, Clearance Rate and Functional Activity in a Rabbit/Infliximab Model

Maiken Lumby Henriksen; Ane Teisner; Jens Kjeldsen; Otto Kalliokoski; Jann Hau; Soren Werner Karlskov Hansen

The Effect of Induced Antibodies with Respect to Neutralization, Clearance Rate and Functional Activity in a Rabbit/Infliximab Model

Maiken Lumby Henriksen, Ane Teisner, Jens Kjeldsen, Otto Kalliokoski, Jann Hau, Soren Werner Karlskov Hansen^*

^*Corresponding author for this work

Abstract

Background: Therapeutic antibodies are a developing field for treatment of an expanding number of inflammatory diseases, including Crohn's disease. Treatment with monoclonal antibodies is frequently hampered by development of anti-drug antibodies (ADAs) that may compromise the treatment. Materials and Methods: We addressed this issue in a rabbit model of treatment with the anti-tumor-necrosis factor alpha (TNF) antibody, infliximab (IFX). We developed an inhibition ELISA to selectively measure absolute concentrations of neutralizing antibodies and another ELISA for measuring the concentration of functional IFX in the circulation. Results: We found that the concentration of functional IFX was inversely proportional to the concentration of neutralizing antibodies. Conclusion: Administration of IFX to rabbits showed diversity in immune responses/tolerance toward IFX, corresponding to responses observed in patients. The applied assay technology is easily adapted to human plasma samples and/or other therapeutic antibodies, including fully humanized antibodies, for which immunogenicity also is observed.

Original language	English
Journal	In Vivo
Volume	30
Issue number	5
Pages (from-to)	557-565
Number of pages	9
ISSN	0258-851X
Publication status	Published - Sept 2016

Keywords

Immunogenicity
Infliximab
Therapeutic monoclonal antibodies

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://iv.iiarjournals.org/content/30/5/557.abstractLicence: Unspecified

Cite this

@article{e7b7029cf8f249b2bbd73862c148906e,

title = "The Effect of Induced Antibodies with Respect to Neutralization, Clearance Rate and Functional Activity in a Rabbit/Infliximab Model",

abstract = "Background: Therapeutic antibodies are a developing field for treatment of an expanding number of inflammatory diseases, including Crohn's disease. Treatment with monoclonal antibodies is frequently hampered by development of anti-drug antibodies (ADAs) that may compromise the treatment. Materials and Methods: We addressed this issue in a rabbit model of treatment with the anti-tumor-necrosis factor alpha (TNF) antibody, infliximab (IFX). We developed an inhibition ELISA to selectively measure absolute concentrations of neutralizing antibodies and another ELISA for measuring the concentration of functional IFX in the circulation. Results: We found that the concentration of functional IFX was inversely proportional to the concentration of neutralizing antibodies. Conclusion: Administration of IFX to rabbits showed diversity in immune responses/tolerance toward IFX, corresponding to responses observed in patients. The applied assay technology is easily adapted to human plasma samples and/or other therapeutic antibodies, including fully humanized antibodies, for which immunogenicity also is observed.",

keywords = "Immunogenicity, Infliximab, Therapeutic monoclonal antibodies",

author = "Henriksen, {Maiken Lumby} and Ane Teisner and Jens Kjeldsen and Otto Kalliokoski and Jann Hau and Hansen, {Soren Werner Karlskov}",

year = "2016",

month = sep,

language = "English",

volume = "30",

pages = "557--565",

journal = "In Vivo",

issn = "0258-851X",

publisher = "International Institute of Anticancer Research",

number = "5",

}

TY - JOUR

T1 - The Effect of Induced Antibodies with Respect to Neutralization, Clearance Rate and Functional Activity in a Rabbit/Infliximab Model

AU - Henriksen, Maiken Lumby

AU - Teisner, Ane

AU - Kjeldsen, Jens

AU - Kalliokoski, Otto

AU - Hau, Jann

AU - Hansen, Soren Werner Karlskov

PY - 2016/9

Y1 - 2016/9

N2 - Background: Therapeutic antibodies are a developing field for treatment of an expanding number of inflammatory diseases, including Crohn's disease. Treatment with monoclonal antibodies is frequently hampered by development of anti-drug antibodies (ADAs) that may compromise the treatment. Materials and Methods: We addressed this issue in a rabbit model of treatment with the anti-tumor-necrosis factor alpha (TNF) antibody, infliximab (IFX). We developed an inhibition ELISA to selectively measure absolute concentrations of neutralizing antibodies and another ELISA for measuring the concentration of functional IFX in the circulation. Results: We found that the concentration of functional IFX was inversely proportional to the concentration of neutralizing antibodies. Conclusion: Administration of IFX to rabbits showed diversity in immune responses/tolerance toward IFX, corresponding to responses observed in patients. The applied assay technology is easily adapted to human plasma samples and/or other therapeutic antibodies, including fully humanized antibodies, for which immunogenicity also is observed.

AB - Background: Therapeutic antibodies are a developing field for treatment of an expanding number of inflammatory diseases, including Crohn's disease. Treatment with monoclonal antibodies is frequently hampered by development of anti-drug antibodies (ADAs) that may compromise the treatment. Materials and Methods: We addressed this issue in a rabbit model of treatment with the anti-tumor-necrosis factor alpha (TNF) antibody, infliximab (IFX). We developed an inhibition ELISA to selectively measure absolute concentrations of neutralizing antibodies and another ELISA for measuring the concentration of functional IFX in the circulation. Results: We found that the concentration of functional IFX was inversely proportional to the concentration of neutralizing antibodies. Conclusion: Administration of IFX to rabbits showed diversity in immune responses/tolerance toward IFX, corresponding to responses observed in patients. The applied assay technology is easily adapted to human plasma samples and/or other therapeutic antibodies, including fully humanized antibodies, for which immunogenicity also is observed.

KW - Immunogenicity

KW - Infliximab

KW - Therapeutic monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=84992084016&partnerID=8YFLogxK

M3 - Journal article

AN - SCOPUS:84992084016

SN - 0258-851X

VL - 30

SP - 557

EP - 565

JO - In Vivo

JF - In Vivo

IS - 5

ER -

The Effect of Induced Antibodies with Respect to Neutralization, Clearance Rate and Functional Activity in a Rabbit/Infliximab Model

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this